BJMO - volume 15, issue 1, january 2021
L. Sorber PhD, K. Zwaenepoel PhD, J. Jacobs PhD, C. Rolfo MD, PhD, G. Roeyen MD, PhD, P. Pauwels MD, PhD
The general aim of this thesis was to determine the optimal workflow of circulating cell-free nucleic acid- (cfNA) based liquid biopsy for implementation in routine clinical practice. We started by evaluating several pre-analytical variables of the liquid biopsy workflow. We examined several cfDNA isolation kits, determined the optimal centrifugation protocol for both cfDNA and cfRNA, and determined the cfDNA stabilising efficiency of (specialised) blood collection tube (BCT). Next, we focused on the clinical applicability of liquid biopsy in non-small cell lung cancer (NSCLC). Based on this work, we specified recommendations regarding (pre-) analytical and biological variables to ensure successful liquid biopsy analysis.
(BELG J MED ONCOL 2021;15(1):48-50)
Read moreBJMO - volume 13, issue 2, march 2019
J. Jacobs PhD, T. Flieswasser MSc, F. Lardon PhD, E. Smits PhD, P. Pauwels MD, PhD
Under normal conditions, CD70, member of the tumour necrosis factor family, is only transiently expressed on activated T and B cells. Instead, constitutive expression of CD70 has been described on malignant cells in a range of solid and haematological malignancies. Through its receptor, CD27, the expression of CD70 can facilitate evasion of the immune system by three important mechanisms: induction of T cell apoptosis, T cell exhaustion and increasing the amount of suppressive regulatory T cells. The general aim of this thesis was to investigate the role of CD70 in solid tumour types and explore promising combination strategies for anti-CD70 therapy. Thereby, we focused on the role of CD70 in non-small cell lung cancer and colorectal cancer.
(BELG J MED ONCOL 2019;13(2):54–59)
Read moreBJMO - , issue ,
C. Boeckx PhD, E. Smits PhD, J. Jacobs PhD
Nowadays, PD-L1/PD-1 immune checkpoint inhibitors have become a key part of the clinical management of cancer. Improving our understanding of anti-cancer immune response, which is influenced by a complex set of tumour, host and environment factors, will further broaden the clinical applicability of these treatments. In this review, we discuss several approaches to evaluate the tumour microenvironment (TME) in clinical practice as well as a view on future predictive biomarkers for cancer immunotherapy.
Read moreBJMO - volume 12, issue 9, february 2018
C. Boeckx PhD, E. Smits PhD, J. Jacobs PhD
Nowadays, PD-L1/PD-1 immune checkpoint inhibitors have become a key part of the clinical management of cancer. Improving our understanding of anti-cancer immune response, which is influenced by a complex set of tumour, host and environment factors, will further broaden the clinical applicability of these treatments. In this review, we discuss several approaches to evaluate the tumour microenvironment (TME) in clinical practice as well as a view on future predictive biomarkers for cancer immunotherapy.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
